The Scientist Turned VC Funding the Cure for Aging with Omri Amirav-Drory

What if aging isn’t inevitable — but a solvable problem?And what if the biggest opportunity in healthcare isn’t treating disease, but preventing it entirely?In this episode of Ventures from the Valley, I sit down with Omri Amirav-Drory, General Partner at NFX, to explore one of the most ambitious frontiers in venture capital: longevity, biotech, and the intersection of biology and technology.Omri leads pre-seed and seed investments at NFX and focuses on what he believes is the ultimate mission — ending involuntary death. We talk openly about why aging is the root cause behind most diseases, how AI is transforming biotech, and why longevity represents a $38 trillion per year opportunity in additional healthy life.This is a deep, honest conversation about conviction, risk, optimism, and why the future of healthcare looks nothing like today’s system.⸻In this episode, we discuss: • Why aging is the root cause of 9 out of 10 deadly diseases • The real difference between lifespan and healthspan • Why longevity could unlock $38T per year in economic value • How NFX evaluates early-stage biotech and tech-bio startups • The power-law logic behind seed investing • Why most VCs miss the biggest opportunities by being pessimistic • AI’s three major waves in biotech and drug discovery • Why GLP-1 drugs changed healthcare economics forever • Precision medicine, biomarkers, and the limits of simulation • Whether humans alive today could realistically live to 160 • Replacement biology, regeneration, and the ethics of enhancement❓ Do you believe aging will be cured in our lifetime — or is it science fiction?___________________________________________________________________________R136 Ventures - a Silicon Valley-based multi-stage VC firm with a focus on scaling mid and late-stage B2B and fintech startups.Our mission is to propel creative entrepreneurs to a faster growth trajectory. We help founders scale their mid-to-late stage startups, bringing with us a distinctive fusion of expertise and past experiences that are key in unlocking their true potential. With many of our team having previously held CEO, CTO and other c-level positions, we understand the challenges and opportunities of both startups and major corporations. Our contribution doesn't just stop at vision and strategy; we actively shape your execution and help in talent acquisition. With a legacy of managing assets exceeding $400 million and having financially backed more than  30 innovative companies, our record speaks for itself.🌐 Learn more: https://www.r136.vc/